Role and effective therapeutic target of gut microbiota in NAFLD/NASH (Review)

  • Authors:
    • Qun Liu
    • Shousheng Liu
    • Lizhen Chen
    • Zhenzhen Zhao
    • Shuixian Du
    • Quanjiang Dong
    • Yongning Xin
    • Shiying Xuan
  • View Affiliations

  • Published online on: July 17, 2019     https://doi.org/10.3892/etm.2019.7781
  • Pages: 1935-1944
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Non‑alcoholic fatty liver disease (NAFLD), the most prevalent chronic liver disease in the world, is affected by numerous extrinsic and intrinsic factors, including lifestyle, environment, diet, genetic susceptibility, metabolic syndrome and gut microbiota. Accumulating evidence has proven that gut dysbiosis is significantly associated with the development and progression of NAFLD, and several highly variable species in gut microbiota have been identified. The gut microbiota contributes to NAFLD by abnormal regulation of the liver‑gut axis, gut microbial components and microbial metabolites, and affects the secretion of bile acids. Due to the key role of the gut microbiota in NAFLD, it has been regarded as a potential target for the pharmacological and clinical treatment of NAFLD. The present review provides a systematic summary of the characterization of gut microbiota and the significant association between the gut microbiota and NAFLD. The possible mechanisms of how the gut microbiota is involved in promoting the development and progression of NAFLD were also discussed. In addition, the potential therapeutic methods for NAFLD based on the gut microbiota were summarized.

References

1 

Borrelli A, Bonelli P, Tuccillo FM, Goldfine ID, Evans JL, Buonaguro FM and Mancini A: Role of gut microbiota and oxidative stress in the progression of non-alcoholic fatty liver disease to hepatocarcinoma: Current and innovative therapeutic approaches. Redox Biol. 15:467–479. 2018. View Article : Google Scholar : PubMed/NCBI

2 

Rinella ME: Nonalcoholic fatty liver disease: A systematic review. JAMA. 313:2263–2273. 2015. View Article : Google Scholar : PubMed/NCBI

3 

Sharma M, Mitnala S, Vishnubhotla RK, Mukherjee R, Reddy DN and Rao PN: The riddle of nonalcoholic fatty liver disease: Progression from nonalcoholic fatty liver to nonalcoholic steatohepatitis. J Clin Exp Hepatol. 5:147–158. 2015. View Article : Google Scholar : PubMed/NCBI

4 

Farrell GC, Wong VW and Chitturi S: NAFLD in Asia-as common and important as in the West. Nat Rev Gastroenterol Hepatol. 10:307–318. 2013. View Article : Google Scholar : PubMed/NCBI

5 

Wong VW: Nonalcoholic fatty liver disease in Asia: A story of growth. J Gastroenterol Hepatol. 28:18–23. 2013. View Article : Google Scholar : PubMed/NCBI

6 

Chitturi S, Wong VW and Farrell G: Nonalcoholic fatty liver in Asia: Firmly entrenched and rapidly gaining ground. J Gastroenterol Hepatol. 26 (Suppl 1):S163–S172. 2011. View Article : Google Scholar

7 

Simeone JC, Bae JP, Hoogwerf BJ, Li Q, Haupt A, Ali AK, Boardman MK and Nordstrom BL: Clinical course of nonalcoholic fatty liver disease: An assessment of severity, progression, and outcomes. Clin Epidemiol. 9:679–688. 2017. View Article : Google Scholar : PubMed/NCBI

8 

Neuschwander-Tetri BA and Caldwell SH: Nonalcoholic steatohepatitis: Summary of an AASLD single topic conference. Hepatology. 37:1202–1219. 2003. View Article : Google Scholar : PubMed/NCBI

9 

Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, Ferrell LD, Liu YC, Torbenson MS, Unalp-Arida A, et al: Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 41:1313–1321. 2005. View Article : Google Scholar : PubMed/NCBI

10 

Lonardo A, Byrne CD, Caldwell SH, Cortez-Pinto H and Targher G: Global epidemiology of nonalcoholic fatty liver disease: Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 64:1388–1389. 2016. View Article : Google Scholar : PubMed/NCBI

11 

Kim D, Kim WR, Talwalkar JA, Kim HJ and Ehman RL: Advanced fibrosis in nonalcoholic fatty liver disease: Noninvasive assessment with MR elastography. Radiology. 268:411–419. 2013. View Article : Google Scholar : PubMed/NCBI

12 

Kim D, Touros A and Kim WR: Nonalcoholic fatty liver disease and metabolic syndrome. Clin Liver Dis. 22:133–140. 2018. View Article : Google Scholar : PubMed/NCBI

13 

Wong VW, Vergniol J, Wong GL, Foucher J, Chan HL, Le Bail B, Choi PC, Kowo M, Chan AW, Merrouche W, et al: Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease. Hepatology. 51:454–462. 2010. View Article : Google Scholar : PubMed/NCBI

14 

European Association for the Study of the Liver (EASL)1; European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO), . EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol. 64:1388–1402. 2016. View Article : Google Scholar : PubMed/NCBI

15 

Leung C, Rivera L, Furness JB and Angus PW: The role of the gut microbiota in NAFLD. Nat Rev Gastroenterol Hepatol. 13:412–425. 2016. View Article : Google Scholar : PubMed/NCBI

16 

Meex RCR and Watt MJ: Hepatokines: Linking nonalcoholic fatty liver disease and insulin resistance. Nat Rev Endocrinol. 13:509–520. 2017. View Article : Google Scholar : PubMed/NCBI

17 

Ricketts ML and Ferguson BS: Polyphenols: Novel signaling pathways. Curr Pharm Des. 24:158–170. 2018. View Article : Google Scholar : PubMed/NCBI

18 

Zhu J, Wan X, Wang Y, Zhu K, Li C, Yu C and Li Y: Serum fetuin B level increased in subjects of nonalcoholic fatty liver disease: A case-control study. Endocrine. 56:208–211. 2017. View Article : Google Scholar : PubMed/NCBI

19 

Day CP and James OF: Steatohepatitis: A tale of two ‘hits’? Gastroenterology. 114:842–845. 1998. View Article : Google Scholar : PubMed/NCBI

20 

Tilg H and Moschen AR: Evolution of inflammation in nonalcoholic fatty liver disease: The multiple parallel hits hypothesis. Hepatology. 52:1836–1846. 2010. View Article : Google Scholar : PubMed/NCBI

21 

Tiniakos DG, Vos MB and Brunt EM: Nonalcoholic fatty liver disease: Pathology and pathogenesis. Annu Rev Pathol. 5:145–171. 2010. View Article : Google Scholar : PubMed/NCBI

22 

Birerdinc A and Younossi ZM: Epigenome-wide association studies provide insight into the pathogenesis of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. Ann Hepatol. 17:11–13. 2018. View Article : Google Scholar : PubMed/NCBI

23 

Benedict M and Zhang X: Non-alcoholic fatty liver disease: An expanded review. World J Hepatol. 9:715–732. 2017. View Article : Google Scholar : PubMed/NCBI

24 

Li TT, Li TH, Peng J, He B, Liu LS, Wei DH, Jiang ZS, Zheng XL and Tang ZH: TM6SF2: A novel target for plasma lipid regulation. Atherosclerosis. 268:170–176. 2018. View Article : Google Scholar : PubMed/NCBI

25 

Del Campo JA, Gallego-Durán R, Gallego P and Grande L: Genetic and epigenetic regulation in nonalcoholic fatty liver disease (NAFLD). Int J Mol Sci. 19:E9112018. View Article : Google Scholar : PubMed/NCBI

26 

Park JS, Seo JH and Youn HS: Gut microbiota and clinical disease: Obesity and nonalcoholic Fatty liver disease. Pediatr Gastroenterol Hepatol Nutr. 16:22–27. 2013. View Article : Google Scholar : PubMed/NCBI

27 

Qin J, Li R, Raes J, Arumugam M, Burgdorf KS, Manichanh C, Nielsen T, Pons N, Levenez F, Yamada T, et al: A human gut microbial gene catalogue established by metagenomic sequencing. Nature. 464:59–65. 2010. View Article : Google Scholar : PubMed/NCBI

28 

Santacruz A, Collado MC, García-Valdés L, Segura MT, Martín-Lagos JA, Anjos T, Martí-Romero M, Lopez RM, Florido J and Sanz Y: Gut microbiota composition is associated with body weight, weight gain and biochemical parameters in pregnant women. Br J Nutr. 104:83–92. 2010. View Article : Google Scholar : PubMed/NCBI

29 

Ursell LK, Clemente JC, Rideout JR, Gevers D, Caporaso JG and Knight R: The interpersonal and intrapersonal diversity of human-associated microbiota in key body sites. J Allergy Clin Immunol. 129:1204–1208. 2012. View Article : Google Scholar : PubMed/NCBI

30 

Neish AS: Microbes in gastrointestinal health and disease. Gastroenterology. 136:65–80. 2009. View Article : Google Scholar : PubMed/NCBI

31 

Mokhtari Z, Gibson DL and Hekmatdoost A: Nonalcoholic fatty liver disease, the gut microbiome, and diet. Adv Nutr. 8:240–252. 2017. View Article : Google Scholar : PubMed/NCBI

32 

Clemente JC, Ursell LK, Parfrey LW and Knight R: The impact of the gut microbiota on human health: An integrative view. Cell. 148:1258–1270. 2012. View Article : Google Scholar : PubMed/NCBI

33 

Ley RE, Turnbaugh PJ, Klein S and Gordon JI: Microbial ecology: Human gut microbes associated with obesity. Nature. 444:1022–1023. 2006. View Article : Google Scholar : PubMed/NCBI

34 

Zhang X, Chen Y, Zhu J, Zhang M, Ho CT, Huang Q and Cao J: Metagenomics analysis of gut microbiota in a high fat diet-induced obesity mouse model fed with (−)-epigallocatechin 3-O-(3-O-Methyl) gallate (EGCG3′'Me). Mol Nutr Food Res. 62:e18002742018. View Article : Google Scholar : PubMed/NCBI

35 

Devillard E, McIntosh FM, Duncan SH and Wallace RJ: Metabolism of linoleic acid by human gut bacteria: Different routes for biosynthesis of conjugated linoleic acid. J Bacteriol. 189:2566–2570. 2007. View Article : Google Scholar : PubMed/NCBI

36 

Li X and Li C: Analysis of changes in intestinal flora and intravascular inflammation and coronary heart disease in obese patients. Exp Ther Med. 15:4538–4542. 2018.PubMed/NCBI

37 

Li CY, Dempsey JL, Wang D, Lee S, Weigel KM, Fei Q, Bhatt DK, Prasad B, Raftery D, Gu H and Cui JY: PBDEs altered gut microbiome and bile acid homeostasis in Male C57BL/6 mice. Drug Metab Dispos. 46:1226–1240. 2018. View Article : Google Scholar : PubMed/NCBI

38 

Zununi Vahed S, Moghaddas Sani H, Rahbar Saadat Y, Barzegari A and Omidi Y: Type 1 diabetes: Through the lens of human genome and metagenome interplay. Biomed Pharmacother. 104:332–342. 2018. View Article : Google Scholar : PubMed/NCBI

39 

Baddini Feitoza A, Fernandes Pereira A, Ferreira da Costa N and Gonçalves Ribeiro B: Conjugated linoleic acid (CLA): Effect modulation of body composition and lipid profile. Nutr Hosp. 24:422–428. 2009.PubMed/NCBI

40 

Zhang C, Björkman A, Cai K, Liu G, Wang C, Li Y, Xia H, Sun L, Kristiansen K, Wang J, et al: Impact of a 3-months vegetarian diet on the gut microbiota and immune repertoire. Front Immunol. 9:9082018. View Article : Google Scholar : PubMed/NCBI

41 

Shin NR, Whon TW and Bae JW: Proteobacteria: Microbial signature of dysbiosis in gut microbiota. Trends Biotechnol. 33:496–503. 2015. View Article : Google Scholar : PubMed/NCBI

42 

Turnbaugh PJ, Ley RE, Mahowald MA, Magrini V, Mardis ER and Gordon JI: An obesity-associated gut microbiome with increased capacity for energy harvest. Nature. 444:1027–1031. 2006. View Article : Google Scholar : PubMed/NCBI

43 

Membrez M, Blancher F, Jaquet M, Bibiloni R, Cani PD, Burcelin RG, Corthesy I, Corthesy I, Macé K and Chou CJ: Gut microbiota modulation with norfloxacin and ampicillin enhances glucose tolerance in mice. FASEB J. 22:2416–2426. 2008. View Article : Google Scholar : PubMed/NCBI

44 

Azad MB, Bridgman SL, Becker AB and Kozyrskyj AL: Infant antibiotic exposure and the development of childhood overweight and central adiposity. Int J Obes (Lond). 38:1290–1298. 2014. View Article : Google Scholar : PubMed/NCBI

45 

Cho I, Yamanishi S, Cox L, Methé BA, Zavadil J, Li K, Gao Z, Mahana D, Raju K, Teitler I, et al: Antibiotics in early life alter the murine colonic microbiome and adiposity. Nature. 488:621–626. 2012. View Article : Google Scholar : PubMed/NCBI

46 

Vrieze A, Van Nood E, Holleman F, Salojärvi J, Kootte RS, Bartelsman JF, Dallinga-Thie GM, Ackermans MT, Serlie MJ, Oozeer R, et al: Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome. Gastroenterology. 143:913–916.e7. 2012. View Article : Google Scholar : PubMed/NCBI

47 

Poeta M, Pierri L and Vajro P: Gut-liver axis derangement in non-alcoholic fatty liver disease. Children (Basel). 4:E662017.PubMed/NCBI

48 

Zorn AM and Wells JM: Vertebrate endoderm development and organ formation. Annu Rev Cell Dev Biol. 25:221–251. 2009. View Article : Google Scholar : PubMed/NCBI

49 

Baffy G: Potential mechanisms linking gut microbiota and portal hypertension. Liver Int. 39:598–609. 2019. View Article : Google Scholar : PubMed/NCBI

50 

Clemente MG, Mandato C, Poeta M and Vajro P: Pediatric non-alcoholic fatty liver disease: Recent solutions, unresolved issues, and future research directions. World J Gastroenterol. 22:8078–8093. 2016. View Article : Google Scholar : PubMed/NCBI

51 

Compare D, Coccoli P, Rocco A, Nardone OM, De Maria S, Carteni M and Nardone G: Gut-liver axis: The impact of gut microbiota on non alcoholic fatty liver disease. Nutr Metab Cardiovasc Dis. 22:471–476. 2012. View Article : Google Scholar : PubMed/NCBI

52 

Rafiei R, Bemanian M, Rafiei F, Bahrami M, Fooladi L, Ebrahimi G, Hemmat A and Torabi Z: Liver disease symptoms in non-alcoholic fatty liver disease and small intestinal bacterial overgrowth. Rom J Intern Med. 56:85–89. 2018.PubMed/NCBI

53 

Sabaté JM, Jouët P, Harnois F, Mechler C, Msika S, Grossin M and Coffin B: High prevalence of small intestinal bacterial overgrowth in patients with morbid obesity: A contributor to severe hepatic steatosis. Obes Surg. 18:371–377. 2008. View Article : Google Scholar : PubMed/NCBI

54 

King T: Small intestinal bacterial overgrowth and irritable bowel syndrome. JAMA. 292:2213; author reply. 2213–2214. 2004. View Article : Google Scholar : PubMed/NCBI

55 

Wigg AJ, Roberts-Thomson IC, Dymock RB, McCarthy PJ, Grose RH and Cummins AG: The role of small intestinal bacterial overgrowth, intestinal permeability, endotoxaemia, and tumour necrosis factor alpha in the pathogenesis of non-alcoholic steatohepatitis. Gut. 48:206–211. 2001. View Article : Google Scholar : PubMed/NCBI

56 

Ghoshal UC, Baba CS, Ghoshal U, Alexander G, Misra A, Saraswat VA and Choudhuri G: Low-grade small intestinal bacterial overgrowth is common in patients with non-alcoholic steatohepatitis on quantitative jejunal aspirate culture. Indian J Gastroenterol. 36:390–399. 2017. View Article : Google Scholar : PubMed/NCBI

57 

Boulangé CL, Neves AL, Chilloux J, Nicholson JK and Dumas ME: Impact of the gut microbiota on inflammation, obesity, and metabolic disease. Genome Med. 8:422016. View Article : Google Scholar : PubMed/NCBI

58 

Shanab AA, Scully P, Crosbie O, Buckley M, O'Mahony L, Shanahan F, Gazareen S, Murphy E and Quigley EM: Small intestinal bacterial overgrowth in nonalcoholic steatohepatitis: Association with toll-like receptor 4 expression and plasma levels of interleukin 8. Dig Dis Sci. 56:1524–1534. 2011. View Article : Google Scholar : PubMed/NCBI

59 

Fukunishi S, Sujishi T, Takeshita A, Ohama H, Tsuchimoto Y, Asai A, Tsuda Y and Higuchi K: Lipopolysaccharides accelerate hepatic steatosis in the development of nonalcoholic fatty liver disease in Zucker rats. J Clin Biochem Nutr. 54:39–44. 2014. View Article : Google Scholar : PubMed/NCBI

60 

Ferolla SM, Armiliato GN, Couto CA and Ferrari TC: The role of intestinal bacteria overgrowth in obesity-related nonalcoholic fatty liver disease. Nutrients. 6:5583–5599. 2014. View Article : Google Scholar : PubMed/NCBI

61 

D'Mello C, Ronaghan N, Zaheer R, Dicay M, Le T, MacNaughton WK, Surrette MG and Swain MG: Probiotics improve inflammation-associated sickness behavior by altering communication between the peripheral immune system and the brain. J Neurosci. 35:10821–10830. 2015. View Article : Google Scholar : PubMed/NCBI

62 

Mutlu E, Keshavarzian A, Engen P, Forsyth CB, Sikaroodi M and Gillevet P: Intestinal dysbiosis: A possible mechanism of alcohol-induced endotoxemia and alcoholic steatohepatitis in rats. Alcohol Clin Exp Res. 33:1836–1846. 2009. View Article : Google Scholar : PubMed/NCBI

63 

Li F, Duan K, Wang C, McClain C and Feng W: Probiotics and alcoholic liver disease: Treatment and potential mechanisms. Gastroenterol Res Pract. 2016:54914652016. View Article : Google Scholar : PubMed/NCBI

64 

Leavy O: Innate immunity: New PAMP discovered. Nat Rev Immunol. 15:402–403. 2015. View Article : Google Scholar

65 

Ruiz AG, Casafont F, Crespo J, Cayón A, Mayorga M, Estebanez A, Fernadez-Escalante JC and Pons-Romero F: Lipopolysaccharide-binding protein plasma levels and liver TNF-alpha gene expression in obese patients: Evidence for the potential role of endotoxin in the pathogenesis of non-alcoholic steatohepatitis. Obes Surg. 17:1374–1380. 2007. View Article : Google Scholar : PubMed/NCBI

66 

Liu J, Zhuang ZJ, Bian DX, Ma XJ, Xun YH, Yang WJ, Luo Y, Liu YL, Jia L, Wang Y, et al: Toll-like receptor-4 signalling in the progression of non-alcoholic fatty liver disease induced by high-fat and high-fructose diet in mice. Clin Exp Pharmacol Physiol. 41:482–488. 2014. View Article : Google Scholar : PubMed/NCBI

67 

Leoni S, Tovoli F, Napoli L, Serio I, Ferri S and Bolondi L: Current guidelines for the management of non-alcoholic fatty liver disease: A systematic review with comparative analysis. World J Gastroenterol. 24:3361–3373. 2018. View Article : Google Scholar : PubMed/NCBI

68 

Nobili V, Carpino G, Alisi A, Franchitto A, Alpini G, De Vito R, Onori P, Alvaro D and Gaudio E: Hepatic progenitor cells activation, fibrosis, and adipokines production in pediatric nonalcoholic fatty liver disease. Hepatology. 56:2142–2153. 2012. View Article : Google Scholar : PubMed/NCBI

69 

Yoon HJ and Cha BS: Pathogenesis and therapeutic approaches for non-alcoholic fatty liver disease. World J Hepatol. 6:800–811. 2014. View Article : Google Scholar : PubMed/NCBI

70 

Temple JL, Cordero P, Li J, Nguyen V and Oben JA: A guide to non-alcoholic fatty liver disease in childhood and adolescence. Int J Mol Sci. 17:9472016. View Article : Google Scholar

71 

Berardis S and Sokal E: Pediatric non-alcoholic fatty liver disease: An increasing public health issue. Eur J Pediatr. 173:131–139. 2014. View Article : Google Scholar : PubMed/NCBI

72 

Yu Q, Jiang Z and Zhang L: Bile acid regulation: A novel therapeutic strategy in non-alcoholic fatty liver disease. Pharmacol Ther. 190:81–90. 2018. View Article : Google Scholar : PubMed/NCBI

73 

Chow MD, Lee YH and Guo GL: The role of bile acids in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Mol Aspects Med. 56:34–44. 2017. View Article : Google Scholar : PubMed/NCBI

74 

Chávez-Talavera O, Tailleux A, Lefebvre P and Staels B: Bile acid control of metabolism and inflammation in obesity, type 2 diabetes, dyslipidemia, and nonalcoholic fatty liver disease. Gastroenterology. 152:1679–1694.e3. 2017. View Article : Google Scholar : PubMed/NCBI

75 

Park MY, Kim SJ, Ko EK, Ahn SH, Seo H and Sung MK: Gut microbiota-associated bile acid deconjugation accelerates hepatic steatosis in ob/ob mice. J Appl Microbiol. 121:800–810. 2016. View Article : Google Scholar : PubMed/NCBI

76 

Janssen AWF, Houben T, Katiraei S, Dijk W, Boutens L, van der Bolt N, Wang Z, Brown JM, Hazen SL, Mandard S, et al: Modulation of the gut microbiota impacts nonalcoholic fatty liver disease: A potential role for bile acids. J Lipid Res. 58:1399–1416. 2017. View Article : Google Scholar : PubMed/NCBI

77 

Puri P, Daita K, Joyce A, Mirshahi F, Santhekadur PK, Cazanave S, Luketic VA, Siddiqui MS, Boyett S, Min HK, et al: The presence and severity of nonalcoholic steatohepatitis is associated with specific changes in circulating bile acids. Hepatology. Jul 11–2017.(Epub ahead of print) Doi: 10.1002/hep.29359.

78 

Zhang L, Xie C, Nichols RG, Chan SH, Jiang C, Hao R, Smith PB, Cai J, Simons MN, Hatzakis E, et al: Farnesoid X receptor signaling shapes the gut microbiota and controls hepatic lipid metabolism. mSystems. 1:e00070–16. 2016. View Article : Google Scholar : PubMed/NCBI

79 

Sepe V, Distrutti E, Fiorucci S and Zampella A: Farnesoid X receptor modulators 2014-present: A patent review. Expert Opin Ther Pat. 28:351–364. 2018. View Article : Google Scholar : PubMed/NCBI

80 

Cruz-Ramón V, Chinchilla-López P, Ramírez-Pérez O and Méndez-Sánchez N: Bile acids in nonalcoholic fatty liver disease: New concepts and therapeutic advances. Ann Hepatol. 16 (Suppl 1: S3-S105):S58–S67. 2017. View Article : Google Scholar

81 

Belei O, Olariu L, Dobrescu A, Marcovici T and Marginean O: The relationship between non-alcoholic fatty liver disease and small intestinal bacterial overgrowth among overweight and obese children and adolescents. J Pediatr Endocrinol Metab. 30:1161–1168. 2017. View Article : Google Scholar : PubMed/NCBI

82 

Alves CC, Waitzberg DL, de Andrade LS, Dos Santos Aguiar L, Reis MB, Guanabara CC, Júnior OA, Ribeiro DA and Sala P: Prebiotic and synbiotic modifications of beta oxidation and lipogenic gene expression after experimental hypercholesterolemia in rat liver. Front Microbiol. 8:20102017. View Article : Google Scholar : PubMed/NCBI

83 

Xu RY, Wan YP, Fang QY, Lu W and Cai W: Supplementation with probiotics modifies gut flora and attenuates liver fat accumulation in rat nonalcoholic fatty liver disease model. J Clin Biochem Nutr. 50:72–77. 2012. View Article : Google Scholar : PubMed/NCBI

84 

Raso GM, Simeoli R, Iacono A, Santoro A, Amero P, Paciello O, Russo R, D'Agostino G, Di Costanzo M, Canani RB, et al: Effects of a Lactobacillus paracasei B21060 based synbiotic on steatosis, insulin signaling and toll-like receptor expression in rats fed a high-fat diet. J Nutr Biochem. 25:81–90. 2014. View Article : Google Scholar : PubMed/NCBI

85 

Nobili V, Putignani L, Mosca A, Chierico FD, Vernocchi P, Alisi A, Stronati L, Cucchiara S, Toscano M and Drago L: Bifidobacteria and Lactobacilli in the gut microbiome of children with non-alcoholic fatty liver disease: Which strains act as health players? Arch Med Sci. 14:81–87. 2018. View Article : Google Scholar : PubMed/NCBI

86 

Bakker GJ and Nieuwdorp M: Fecal microbiota transplantation: Therapeutic potential for a multitude of diseases beyond Clostridium difficile. Microbiol Spectr. 5:2017. View Article : Google Scholar : PubMed/NCBI

87 

de Groot PF, Frissen MN, de Clercq NC and Nieuwdorp M: Fecal microbiota transplantation in metabolic syndrome: History, present and future. Gut Microbes. 8:253–267. 2017. View Article : Google Scholar : PubMed/NCBI

88 

Woodhouse CA, Patel VC, Singanayagam A and Shawcross DL: Review article: The gut microbiome as a therapeutic target in the pathogenesis and treatment of chronic liver disease. Aliment Pharmacol Ther. 47:192–202. 2018. View Article : Google Scholar : PubMed/NCBI

89 

Zhou D, Pan Q, Shen F, Cao HX, Ding WJ, Chen YW and Fan JG: Total fecal microbiota transplantation alleviates high-fat diet-induced steatohepatitis in mice via beneficial regulation of gut microbiota. Sci Rep. 7:15292017. View Article : Google Scholar : PubMed/NCBI

90 

Le Roy T, Llopis M, Lepage P, Bruneau A, Rabot S, Bevilacqua C, Martin P, Philippe C, Walker F, Bado A, et al: Intestinal microbiota determines development of non-alcoholic fatty liver disease in mice. Gut. 62:1787–1794. 2013. View Article : Google Scholar : PubMed/NCBI

91 

Gutiérrez-Rodelo C, Roura-Guiberna A and Olivares-Reyes JA: Molecular mechanisms of insulin resistance: An update. Gac Med Mex. 153:214–228. 2017.(In Spanish). PubMed/NCBI

92 

Manco M: Insulin resistance and NAFLD: A dangerous liaison beyond the genetics. Children (Basel). 4:E742017.PubMed/NCBI

93 

Montandon SA and Jornayvaz FR: Effects of antidiabetic drugs on gut microbiota composition. Genes (Basel). 8:E2502017. View Article : Google Scholar : PubMed/NCBI

94 

Sumida Y, Seko Y and Yoneda M; Japan Study Group of NAFLD (JSG-NAFLD), : Novel antidiabetic medications for non-alcoholic fatty liver disease with type 2 diabetes mellitus. Hepatol Res. 47:266–280. 2017. View Article : Google Scholar : PubMed/NCBI

95 

Pernicova I and Korbonits M: Metformin-mode of action and clinical implications for diabetes and cancer. Nat Rev Endocrinol. 10:143–156. 2014. View Article : Google Scholar : PubMed/NCBI

96 

Napolitano A, Miller S, Nicholls AW, Baker D, Van Horn S, Thomas E, Rajpal D, Spivak A, Brown JR and Nunez DJ: Novel gut-based pharmacology of metformin in patients with type 2 diabetes mellitus. PLoS One. 9:e1007782014. View Article : Google Scholar : PubMed/NCBI

97 

Brunkwall L and Orho-Melander M: The gut microbiome as a target for prevention and treatment of hyperglycaemia in type 2 diabetes: From current human evidence to future possibilities. Diabetologia. 60:943–951. 2017. View Article : Google Scholar : PubMed/NCBI

98 

Shin NR, Lee JC, Lee HY, Kim MS, Whon TW, Lee MS and Bae JW: An increase in the Akkermansia spp. population induced by metformin treatment improves glucose homeostasis in diet-induced obese mice. Gut. 63:727–735. 2014. View Article : Google Scholar : PubMed/NCBI

99 

Lee H and Ko G: Effect of metformin on metabolic improvement and gut microbiota. Appl Environ Microbiol. 80:5935–5943. 2014. View Article : Google Scholar : PubMed/NCBI

100 

Do HJ, Lee YS, Ha MJ, Cho Y, Yi H, Hwang YJ, Hwang GS and Shin MJ: Beneficial effects of voglibose administration on body weight and lipid metabolism via gastrointestinal bile acid modification. Endocr J. 63:691–702. 2016. View Article : Google Scholar : PubMed/NCBI

101 

Shin NR, Bose S, Wang JH, Ansari A, Lim SK, Chin YW, Choi HS and Kim H: Flos lonicera combined with metformin ameliorates hepatosteatosis and glucose intolerance in association with gut microbiota modulation. Front Microbiol. 8:22712017. View Article : Google Scholar : PubMed/NCBI

102 

Kishida Y, Okubo H, Ohno H, Oki K and Yoneda M: Effect of miglitol on the suppression of nonalcoholic steatohepatitis development and improvement of the gut environment in a rodent model. J Gastroenterol. 52:1180–1191. 2017. View Article : Google Scholar : PubMed/NCBI

103 

Zhang X, Zhao Y, Xu J, Xue Z, Zhang M, Pang X, Zhang X and Zhao L: Modulation of gut microbiota by berberine and metformin during the treatment of high-fat diet-induced obesity in rats. Sci Rep. 5:144052015. View Article : Google Scholar : PubMed/NCBI

104 

Bai J, Zhu Y and Dong Y: Response of gut microbiota and inflammatory status to bitter melon (Momordica charantia L.) in high fat diet induced obese rats. J Ethnopharmacol. 194:717–726. 2016. View Article : Google Scholar : PubMed/NCBI

105 

Wang L, Li P, Tang Z, Yan X and Feng B: Structural modulation of the gut microbiota and the relationship with body weight: Compared evaluation of liraglutide and saxagliptin treatment. Sci Rep. 6:332512016. View Article : Google Scholar : PubMed/NCBI

106 

Yan X, Feng B, Li P, Tang Z and Wang L: Microflora disturbance during progression of glucose intolerance and effect of sitagliptin: An animal study. J Diabetes Res. 2016:20931712016. View Article : Google Scholar : PubMed/NCBI

107 

Wu H, Esteve E, Tremaroli V, Khan MT, Caesar R, Mannerås-Holm L, Ståhlman M, Olsson LM, Serino M, Planas-Fèlix M, et al: Metformin alters the gut microbiome of individuals with treatment-naive type 2 diabetes, contributing to the therapeutic effects of the drug. Nat Med. 23:850–858. 2017. View Article : Google Scholar : PubMed/NCBI

108 

de la Cuesta-Zuluaga J, Mueller NT, Corrales-Agudelo V, Velásquez-Mejía EP, Carmona JA, Abad JM and Escobar JS: Metformin is associated with higher relative abundance of mucin-degrading akkermansia muciniphila and several short-chain fatty acid-producing microbiota in the gut. Diabetes Care. 40:54–62. 2017. View Article : Google Scholar : PubMed/NCBI

109 

Forslund K, Hildebrand F, Nielsen T, Falony G, Le Chatelier E, Sunagawa S, Prifti E, Vieira-Silva S, Gudmundsdottir V, Pedersen HK, et al: Disentangling type 2 diabetes and metformin treatment signatures in the human gut microbiota. Nature. 528:262–266. 2015. View Article : Google Scholar : PubMed/NCBI

110 

Zhang X, Fang Z, Zhang C, Xia H, Jie Z, Han X, Chen Y and Ji L: Effects of acarbose on the gut microbiota of prediabetic patients: A randomized, double-blind, controlled crossover trial. Diabetes Ther. 8:293–307. 2017. View Article : Google Scholar : PubMed/NCBI

Related Articles

Journal Cover

September 2019
Volume 18 Issue 3

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Liu, Q., Liu, S., Chen, L., Zhao, Z., Du, S., Dong, Q. ... Xuan, S. (2019). Role and effective therapeutic target of gut microbiota in NAFLD/NASH (Review). Experimental and Therapeutic Medicine, 18, 1935-1944. https://doi.org/10.3892/etm.2019.7781
MLA
Liu, Q., Liu, S., Chen, L., Zhao, Z., Du, S., Dong, Q., Xin, Y., Xuan, S."Role and effective therapeutic target of gut microbiota in NAFLD/NASH (Review)". Experimental and Therapeutic Medicine 18.3 (2019): 1935-1944.
Chicago
Liu, Q., Liu, S., Chen, L., Zhao, Z., Du, S., Dong, Q., Xin, Y., Xuan, S."Role and effective therapeutic target of gut microbiota in NAFLD/NASH (Review)". Experimental and Therapeutic Medicine 18, no. 3 (2019): 1935-1944. https://doi.org/10.3892/etm.2019.7781